REVAMP

A phase3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adults Subjects with Moderate to Severe Ulcerative Colitis who are Naive to Targeted Therapies.

For more information please visit https://clinicaltrials.gov/study/NCT06880744

Interested in Volunteering for the Study?

If you would like more information about this study, please call us at 318-212-2822 .